By Michele Maatouk
Date: Monday 10 Nov 2025
(Sharecast News) - US biotech firm Metsera tumbled on Monday after it agreed to be bought by Pfizer in a sweetened $10bn deal, with Denmark's Novo Nordisk refraining from making an increased offer.
Metsera said late on Friday that Pfizer will pay up to $86.25 per share, consisting of $65.60 per...
or login to read the full story
Email this article to a friend
or share it with one of these popular networks:
You are here: news